Business Description
Arch Therapeutics Inc
NAICS : 325413
SIC : 2836
ISIN : US03939W2089
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -8.99 | |||||
Debt-to-Equity | -0.75 | |||||
Debt-to-EBITDA | -1.08 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -103.82 | |||||
Beneish M-Score | -29.46 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.6 | |||||
3-Year EPS without NRI Growth Rate | 17.5 | |||||
3-Year FCF Growth Rate | 41.1 | |||||
3-Year Book Growth Rate | -1 | |||||
Future 3-5Y Total Revenue Growth Rate | 1192.72 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.1 | |||||
Quick Ratio | 0.01 | |||||
Days Inventory | 5402 | |||||
Days Payable | 10776.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -69.4 | |||||
Shareholder Yield % | -366.38 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 38.93 | |||||
Operating Margin % | -3169.13 | |||||
Net Margin % | -8230.2 | |||||
FCF Margin % | -2484.56 | |||||
ROA % | -740.34 | |||||
ROIC % | -69.91 | |||||
ROC (Joel Greenblatt) % | -271375 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 0.08 | |||||
PS Ratio | 7.85 | |||||
EV-to-EBIT | -1.18 | |||||
EV-to-EBITDA | -1.18 | |||||
EV-to-Revenue | 68.77 | |||||
EV-to-FCF | -2.84 | |||||
Earnings Yield (Greenblatt) % | -84.76 | |||||
FCF Yield % | -416.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Arch Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.149 | ||
EPS (TTM) ($) | -2.864 | ||
Beta | -0.47 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 0.8 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 0.8 - 0.8 | ||
Shares Outstanding (Mil) | 4.44 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Arch Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Arch Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Arch Therapeutics Inc Frequently Asked Questions
What is Arch Therapeutics Inc(LTS:0HHJ)'s stock price today?
When is next earnings date of Arch Therapeutics Inc(LTS:0HHJ)?
Does Arch Therapeutics Inc(LTS:0HHJ) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |